Please login to the form below

Not currently logged in
Email:
Password:

Medtronic heart devices approved

The US Food and Drug Administration has approved a new family of implantable cardiac devices from Medtronic that are intended to reduce the number of inappropriate therapeutic shocks that are delivered

The US Food and Drug Administration has approved a new family of implantable cardiac devices from Medtronic that are intended to improve patients' quality of life by significantly reducing the number of inappropriate therapeutic shocks that are delivered.

The new Protecta portfolio of products, which will begin shipments immediately, includes implantable cardioverter-defibrillators (ICDs) and cardiac resynchronisation therapy-defibrillators (CRT-Ds) that use the company's SmartShock Technology, which is based on six algorithms that recognise life-threatening arrhythmias and deliver therapeutic shocks only when appropriate.

A virtual study conducted by Medtronic based on a statistical model found that the technology results in 98 per cent of patients being free of inappropriate shocks one year after implant and 92 per cent being free of inappropriate shocks five years after implant.

Currently, up to one in five patients with implantable defibrillators may experience inappropriate shocks in response to a benign arrhythmia or electrical noise sensed by the device, according to the company.

29th March 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics